by lythamcorp | Dec 18, 2024 | Cadrenal Therapeutics, Cadrenal Therapeutics News, Healthcare
Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan PONTE VEDRA, Fla. – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan...
by lythamcorp | Dec 17, 2024 | Reviva Pharma News
CUPERTINO, Calif., Dec. 16, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
by lythamcorp | Dec 16, 2024 | Reviva Pharma News
CUPERTINO, Calif., Dec. 16, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
by lythamcorp | Dec 16, 2024 | Reviva Pharma News
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinuation – – Full data set from...
by lythamcorp | Dec 16, 2024 | Reviva Pharma News
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinuation – – Full data set from...